Beyond Air

Beyond Air is a clinical-stage medical device and biopharmaceutical company focused on developing innovative treatments for respiratory and other severe lung diseases using nitric oxide (NO). The company primarily serves healthcare providers and patients suffering from conditions such as Persistent Pulmonary Hypertension of the Newborn (PPHN), bronchiolitis, and nontuberculous mycobacteria (NTM) lung disease. Operating in the medical technology and biopharmaceutical markets, Beyond Air's business model revolves around the development, regulatory approval, and commercialization of its proprietary LungFit™ system. This system generates nitric oxide from ambient air, eliminating the need for high-pressure cylinders, thereby simplifying treatment administration and improving patient outcomes. Revenue is generated through the sale and licensing of its medical devices and related services.

Keywords: nitric oxide, respiratory diseases, medical devices, biopharmaceutical, LungFit, PPHN, bronchiolitis, NTM, healthcare, innovation.